CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI)

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

These stocks have an unusual volume in today's session

The company said that its special committee of the board of directors will evaluate the proposed transaction.

CASI stock results show that CASI Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price.

Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to support its portfolio of drugs.

Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!

CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with partial and complete responses, affirming positive safety profiles.